Skip to Content

Hematologic Cancer Trials

A041702: A Randomized Phase III Study of Iburtinib Plus Obinutuzumab Versus Ibrutinib plus Venetoclax and Obinutuzumab in Untreated Older Patients (>70 Years of Age) with Chronic Lymphocytic Leukemia (CLL) 
Aims: The purpose of this study is to discover if adding the drug Venetoclax will be better, the same or worse than the standard treatment and if stopping after 1 year of treatment is possible for those who have no detectable CLL.
Diagnosis: Chronic Lymphocytic Leukemia (CLL)
Principal investigator: David Grinblatt, MD
IRB Approval Number: EH19-149
Sponsor: Alliance for Clinical Trials in Oncology
Contact: Interested patients should contact research nurse Tara Flanagan, RN at 847.570.1768
Open to Enrollment: Yes

EAA173: Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM)
Aims: The purpose of this study is to discover if adding the drug Venetoclax will be better, the same or worse than the standard treatment
Diagnosis: Smoldering Myeloma
Principal investigator: David Grinblatt, MD
IRB Approval Number: EH19-335
Sponsor: ECOG-ACRIN
Contact: Interested patients should contact research nurse Tara Flanagan, RN at 847.570.1768
Open to Enrollment: Yes

A041501: A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody to Frontline Therapy in Young Adults (ages 18-39 years) with Newly Diagnosed Precursor B-Cell ALL.
Aims: The purpose of this study is to test the addition of an investigational drug, inotuzumab in addition to standard treatment for ALL.
Diagnosis: Acute Lymphocytic Leukemia (ALL)
Principal investigator: Lynne Kaminer, MD
IRB Approval Number: EH18-377
Sponsor: Alliance for Clinical Trials in Oncology
Contact: Interested patients should contact research nurse Tara Flanagan, RN at 847.570.1768
Open to Enrollment: Yes

Connect Myeloid:  The myelofibrosis (MF), Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML  Disease Registry
Aims: There are three main purposes of this study: 1. To use the information collected to help better understand patterns for diagnosis, treatment, and outcomes, including disease progression and survival. 2. To use the information to help better understand patterns for the quality of life in patients newly diagnosed with Lower-Risk, Higher-Risk, or unknown risk MDS or AML. 3. To use the results of this study to provide information to help better understand the effect different treatments have on a patient’s disease and on their quality of life.
Diagnosis: Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML)
Principal Investigator: Lynne Kaminer, MD
IRB Approval Number: EH13-390
Sponsor: Celgene, A Bristol Myers Squibb company
Contact: Interested patients should contact research nurse Tara Flanagan, RN at 847.570.1768
Open to Enrollment: Yes

UTX-TGR-205: A Phase 2b Randomized Study to Assess the Efficacy and Safety of Combination of Ublituximab + TGR-1202 with our without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin's Lymphoma
Aims: The purpose of this study is to see how effective the combination of investigational drugs, ublituximab and umbraslisib are when given together compared to when umbralisib is given alone.
Diagnosis: Non-Hodgkin's lymphoma
Principal Investigator: Lynne Kaminer, MD 
IRB Approval Number: EH17-290
Sponsor: TG Therapeutics
Contact: Interested patients should contact research nurse Tara Flanagan, RN at 847.570.1768
Open to Enrollment: Yes

CIBMTR: Protocol for Research Database for Hematopoietic Cell Transplantation, Other Cellular Therapies and Marrow Toxic Injuries 
Aims: The purpose of this study is to collect information on the collection of peripheral blood stem cells, transplant of stem cells, and the outcomes of patients who undergo peripheral blood stem cell transplant
Diagnosis: For patients undergoing a peripheral blood stem cell transplant
Principal Investigator: Lynne Kaminer, MD 
IRB Approval Number: EH15-249
Sponsor: National Marrow Donor Program
Contact: Interested patients should contact research nurse Tara Flanagan, RN at 847.570.1768
Open to Enrollment: Yes